From GlobeNewswire: 2025-02-04 06:30:00

Regeneron Pharmaceuticals reported a 10% increase in fourth quarter 2024 revenues to $3.79 billion. Full-year 2024 revenues increased by 8% to $14.20 billion, excluding Ronapreve sales. Dupixent global net sales increased by 15% in Q4 to $3.70 billion and by 22% in full year 2024 to $14.15 billion. US net sales for EYLEA HD and EYLEA increased by 2% in Q4 to $1.50 billion and by 1% in full year 2024 to $5.97 billion.

Libtayo global net sales rose by 50% in Q4 to $367 million and by 40% in full year 2024 to $1.22 billion. Fourth quarter 2024 GAAP diluted EPS was $8.06, and non-GAAP diluted EPS was $12.07. Regeneron initiated a quarterly cash dividend program and authorized a $3.0 billion share repurchase program. Regulatory applications were submitted for various treatments, including EYLEA HD pre-filled syringe and Dupixent in bullous pemphigoid.

Positive Phase 3 results were reported for EYLEA HD in retinal vein occlusion and Libtayo in high-risk adjuvant cutaneous squamous cell carcinoma. Regeneron’s financial growth in 2024 allowed for the initiation of a dividend program and increased share repurchase capacity. The company is focusing on its blockbuster medicines and progressing investigational candidates for various diseases.

Regeneron has approximately 40 product candidates in clinical development. Key pipeline progress includes meeting the primary endpoint in the Phase 3 trial of EYLEA HD and submitting regulatory applications for various treatments. The company reported positive results from a Phase 3 trial of Libtayo and initiated new studies for other treatments in different disease states.

Regeneron’s financial guidance for 2025 includes a range for GAAP and non-GAAP R&D, SG&A, gross margin on net product sales, COCM, capital expenditures, and effective tax rate. The company’s financial results reflect strong performance, with a focus on growth and innovation in the healthcare industry. Regeneron continues to invest in research and development to bring life-transforming medicines to patients with serious diseases.



Read more at GlobeNewswire:: Regeneron Reports Fourth Quarter and Full Year 2024